GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cogent Biosciences Inc (NAS:COGT) » Definitions » ROE %

COGT (Cogent Biosciences) ROE % : -82.15% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cogent Biosciences ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Cogent Biosciences's annualized net income for the quarter that ended in Sep. 2024 was $-282.54 Mil. Cogent Biosciences's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was $343.94 Mil. Therefore, Cogent Biosciences's annualized ROE % for the quarter that ended in Sep. 2024 was -82.15%.

The historical rank and industry rank for Cogent Biosciences's ROE % or its related term are showing as below:

COGT' s ROE % Range Over the Past 10 Years
Min: -78   Med: -61.44   Max: -32.2
Current: -72.5

During the past 9 years, Cogent Biosciences's highest ROE % was -32.20%. The lowest was -78.00%. And the median was -61.44%.

COGT's ROE % is ranked worse than
66.36% of 1305 companies
in the Biotechnology industry
Industry Median: -43.68 vs COGT: -72.50

Cogent Biosciences ROE % Historical Data

The historical data trend for Cogent Biosciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogent Biosciences ROE % Chart

Cogent Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only -69.21 -56.16 -32.20 -59.69 -74.94

Cogent Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68.02 -77.57 -68.63 -59.28 -82.15

Competitive Comparison of Cogent Biosciences's ROE %

For the Biotechnology subindustry, Cogent Biosciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cogent Biosciences's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cogent Biosciences's ROE % distribution charts can be found below:

* The bar in red indicates where Cogent Biosciences's ROE % falls into.



Cogent Biosciences ROE % Calculation

Cogent Biosciences's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-192.41/( (255.735+257.802)/ 2 )
=-192.41/256.7685
=-74.94 %

Cogent Biosciences's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=-282.536/( (373.223+314.659)/ 2 )
=-282.536/343.941
=-82.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Cogent Biosciences  (NAS:COGT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-282.536/343.941
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-282.536 / 0)*(0 / 406.9755)*(406.9755 / 343.941)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.1833
=ROA %*Equity Multiplier
=N/A %*1.1833
=-82.15 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-282.536/343.941
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-282.536 / -282.536) * (-282.536 / -301.656) * (-301.656 / 0) * (0 / 406.9755) * (406.9755 / 343.941)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9366 * N/A % * 0 * 1.1833
=-82.15 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Cogent Biosciences ROE % Related Terms

Thank you for viewing the detailed overview of Cogent Biosciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cogent Biosciences Business Description

Traded in Other Exchanges
N/A
Address
275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Executives
Fairmount Funds Management Llc 10 percent owner, other: See Remarks 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Evan Kearns officer: Chief Legal Officer AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
John L. Green officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
John Edward Robinson officer: Chief Scientific Officer C/O COGENT BIOSCIENCES, INC., 200 CAMBRIDGE PARK DRIVE, SUITE 2500, CAMBRIDGE MA 02140
Christopher W. Cain director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Peter Evan Harwin director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Arlene Morris director C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Todd Shegog director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Jessica Sachs officer: Chief Medical Officer C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Matthew Ros director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Andrew R Robbins director, officer: President and CEO C/O 3200 WALNUT ST, BOULDER CO 80301
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Management Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018